A Shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 603-614

  Kemp, Zoe ^a   Jones, Alison ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Crosstalk; Estrogen receptor; Human epidermal growth factor receptor 2; Lapatinib; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANASTROZOLE; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; GEFITINIB; LAPATINIB; LETROZOLE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN ACTIVITY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MEDICAL DECISION MAKING; MEDLINE; METASTATIC BREAST CANCER; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL DISEASE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE FEEDBACK; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 82455164238     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0050-0     Document Type: Review

References (47)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, UllrichA, McGuire WL. Human breast cancer: Correlationof relapse and survival with amplification of theHER-2/neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
2. Baselga J, Tripathy D, Mendelsohn J., et al. Phase II study of weekly intravenous recombinanthumanized anti-p185HER2 monoclonal antibody inpatients with HER2/neu-overexpressing metastaticbreast cancer. J Clin Oncol. 1996;14:737-744.
3. Cobleigh MA, Vogel CL, Tripathy D., et al.Multinational study of the efficacy and safetyof humanized anti-HER2 monoclonal antibodyin women who have HER2-overexpressingmetastatic breast cancer that has progressed afterchemotherapy for metastatic disease. J Clin Oncol.1999;17:2639-2648. (Pubitemid 29415219)
4. Wolff AC, Hammond ME, Schwartz J.N., et al. American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations for human epidermal growth factor receptor 2 testingin breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
5. Marty M, Cognetti F, Maraninchi D., et al.Randomized phase II trial of the efficacy andsafety of trastuzumab combined with docetaxelin patients with human epidermal growth factorreceptor 2-positive metastatic breast canceradministered as first-line treatment: The M77001study group. J Clin Oncol. 2005;23:4265-4274. (Pubitemid 46207001)
6. Slamon DJ, Leyland-Jones B, Shak S., et al. Use ofchemotherapy plus a monoclonal antibody againstHER2 for metastatic breast cancer that overexpressesHER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
7. Kaufman B, Mackey JR, Clemens M.R., et al.Trastuzumab plus anastrozole versus anastrozolealone for the treatment of postmenopausal womenwith human epidermal growth factor receptor2-positive, hormone receptor-positive metastaticbreast cancer: Results from the randomized phaseIII TAnDEM study. J Clin Oncol. 2009;27:5529-5537.
8. Johnston S, Pippen J, Jr., Pivot X., et al. Lapatinibcombined with letrozole versus letrozole andplacebo as first-line therapy for postmenopausalhormone receptor-positive metastatic breastcancer. J Clin Oncol. 2009;27:5538-5546.
9. Beatson G. On the treatment of inoperable casesof carcinoma of the mamma: Suggestions for anew method of treatment with illustrative cases.Lancet. 1896;2:112-167.
10. Jensen E. Fate of steroidal estrogens in targettissues. In: Pincus G VE, ed. Biological activitiesof steroids in relation to cancer: New York, NY:Academic Press; 1962:161-174.
11. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN.Breast cancer subtypes based on ER/PR and Her2expression: Comparison of clinicopathologicfeatures and survival. Clin Med Res. 2009;7:4-13.
12. Cunnick GH, Mokbel K. Aromatase inhibitors.Curr Med Res Opin. 2001;17:217-222. (Pubitemid 34003124)
13. Jordan C. Historical perspective on hormonaltherapy of advanced breast cancer. Clin Ther.2002;24(suppl. A):A3-16.
14. Mouridsen HT. Letrozole in advanced breastcancer: The PO25 trial. Breast Cancer Res Treat.2007;105(suppl. 1):19-29. (Pubitemid 47524795)
15. Nabholtz JM, Buzdar A, Pollak M., et al. Anastrozoleis superior to tamoxifen as first-line therapyfor advanced breast cancer in postmenopausalwomen: Results of a North American multicenterrandomized trial. Arimidex Study Group. J ClinOncol. 2000;18:3758-3767.
16. Berry DA, Cirrincione C, Henderson I.C., et al.Estrogen-receptor status and outcomes of modernchemotherapy for patients with node-positivebreast cancer. JAMA. 2006;295:1658-1667.
17. Colleoni M, Viale G, Zahrieh D., et al.Chemotherapy is more effective in patients withbreast cancer not expressing steroid hormonereceptors: A study of preoperative treatment. ClinCancer Res. 2004;10:6622-6628. (Pubitemid 39346559)
18. Andre F, Broglio K, Pusztai L., et al. Estrogen receptor expression and docetaxel efficacy in patients withmetastatic breast cancer: A pooled analysis of fourrandomized trials. Oncologist. 2010;15:476-483.
19. Andre F, Broglio K, Roche H., et al. Estrogenreceptor expression and efficacy of docetaxelcontainingadjuvant chemotherapy in patientswith node-positive breast cancer: Results from apooled analysis. J Clin Oncol. 2008;26:2636-2643.
20. Romond EH, Perez EA, Bryant J., et al. Trastuzumabplus adjuvant chemotherapy for operableHER2-positive breast cancer. N Engl J Med.2005;353:1673-1684. (Pubitemid 41464706)
21. Smith I, Procter M, Gelber R.D., et al. 2-year followupof trastuzumab after adjuvant chemotherapyin HER2-positive breast cancer: A randomisedcontrolled trial. Lancet. 2007;369:29-36. (Pubitemid 46039831)
22. Vogel CL, Cobleigh MA, Tripathy D., et al. Efficacyand safety of trastuzumab as a single agent in firstlinetreatment of HER2-overexpressing metastaticbreast cancer. J Clin Oncol. 2002;20:719-26. (Pubitemid 34111379)
23. Geyer CE, Forster J, Lindquist D., et al. Lapatinibplus capecitabine for HER2-positive advancedbreast cancer. N Engl J Med. 2006;355:2733-2743. (Pubitemid 46021510)
24. Lewis Phillips GD, Li G, Dugger D.L., et al. TargetingHER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.Cancer Res. 2008;68:9280-9290.
25. Andre F, Campone M, O'Regan R., et al. Phase Istudy of everolimus plus weekly paclitaxel andtrastuzumab in patients with metastatic breastcancer pretreated with trastuzumab. J Clin Oncol.2010;28:5110-5115.
26. Ellis MJ, Coop A, Singh B., et al. Letrozole is moreeffective neoadjuvant endocrine therapy thantamoxifen for ErbB-1- and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:evidence from a phase III randomized trial. J ClinOncol. 2001;19:3808-3816. (Pubitemid 32880059)
27. Smith IE, Dowsett M, Ebbs S.R., et al. Neoadjuvanttreatment of postmenopausal breast cancer withanastrozole, tamoxifen, or both in combination:the Immediate Preoperative Anastrozole,Tamoxifen, or Combined with Tamoxifen(IMPACT) multicenter double-blind randomizedtrial. J Clin Oncol. 2005;23:5108-5116. (Pubitemid 46224019)
28. Ellis MJ, Tao Y, Young O., et al. Estrogen-independent proliferation is present in estrogenreceptorHER2-positive primary breast cancer afterneoadjuvant letrozole. J Clin Oncol. 2006;24:3019-3025. (Pubitemid 46638935)
29. Baselga J. First results of the NeoALTTO trial (BIG01-06 / EGF 106903): A phase III, randomized,open label, neoadjuvant study of lapatinib,trastuzumab, and their combination plus paclitaxelin women with HER2-positive primary breastcancer. SABCS. 2010;Abstract 291.
30. Gianni L. Neoadjuvant pertuzumab (P) andtrastuzumab (H): Antitumour and safety analysis ofa randomised phase II study (NeoSphere). SABCS.2010;Abstract S3-2.
31. Untch M, Loibl, S, Bischoff, J. Lapatinib versustrastuzumab in combination with neoadjuvantanthracycline and taxane based chemotherapy:primary efficacy endpoint analysis of the GeparQuinto study (GBG 44). SABCS. 2010;Abstract S3-1.
32. Osborne CK, Coronado-Heinsohn EB, HilsenbeckS.G., et al. Comparison of the effects of a puresteroidal antiestrogen with those of tamoxifen in amodel of human breast cancer. J Natl Cancer Inst.1995;87:746-750.
33. Shou J, Massarweh S, Osborne C.K., et al.Mechanisms of tamoxifen resistance: Increasedestrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst.2004;96:926-935. (Pubitemid 38868139)
34. Read LD, Keith D, Jr., Slamon DJ, KatzenellenbogenBS. Hormonal modulation of HER-2/neuprotooncogene messenger ribonucleic acid andp185 protein expression in human breast cancercell lines. Cancer Res. 1990;50:3947-3951. (Pubitemid 20225611)
35. Dati C, Antoniotti S, Taverna D, Perroteau I,De Bortoli M. Inhibition of c-erbB-2 oncogeneexpression by estrogens in human breast cancercells. Oncogene. 1990;5:1001-1006.
36. Knowlden JM, Hutcheson IR, Jones H.E., et al.Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growthregulatory pathway in tamoxifen-resistant MCF-7cells. Endocrinology. 2003;144:1032-1044. (Pubitemid 36262870)
37. Osborne K, Neven P, Dirix L. Randomised phase II study of gefitinib (IRESSA) or placebo incombination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2007;106(suppl. 1):S107.
38. Cristofanilli M VV, Mangalik A., et al. A phase IImulticentre, double-blind, randomised trial tocompare anastrazole plus gefitinib with anastrazoleplus placebo in postmenopausal women withhormone receptor positive metastatic breastcancer. J Clin Oncol. 2008;26:44s.
39. Marcom PK, Isaacs C, Harris L., et al. Thecombination of letrozole and trastuzumab as firstor second-line biological therapy produces durableresponses in a subset of HER2 positive and ERpositive advanced breast cancers. Breast Cancer ResTreat. 2007;102:43-49. (Pubitemid 46294957)
40. Huober J FP, Paepke S, Kubista E., et al. [Abstract4094] Letrozole in combination with trastuzumabis superior to letrozole monotherapy as first linetreatment in patients with hormone receptorpositive, HER2 postive metastatic breast cancer -results of the eLEcTRA trial. In: San Antonio BreastCoonference 2009. Cancer Res. 2009;69(suppl.):24.
41. Dowsett M, Allred C, Knox J., et al. Relationshipbetween quantitative estrogen and progesteronereceptor expression and human epidermal growthfactor receptor 2 (HER-2) status with recurrence inthe Arimidex, Tamoxifen, Alone or in Combinationtrial. J Clin Oncol. 2008;26:1059-1065.
42. Hu JC, Mokbel K. Does c-erbB2/HER2overexpression predict adjuvant tamoxifen failurein patients with early breast cancer? Eur J SurgOncol. 2001;27:335-337. (Pubitemid 32624531)
43. Mauriac L, Keshaviah A, Debled M., et al. Predictorsof early relapse in postmenopausal women withhormone receptor-positive breast cancer in the BIG1-98 trial. Ann Oncol. 2007;18:859-867. (Pubitemid 47054082)
44. Chu I, Blackwell K, Chen S, Slingerland J. The dualErbB1/ErbB2 inhibitor, lapatinib (GW572016),cooperates with tamoxifen to inhibit both cellproliferation- and estrogen-dependent geneexpression in antiestrogen- resistant breast cancer.Cancer Res. 2005;65:18-25. (Pubitemid 40070791)
45. Di Leo A, Gomez HL, Aziz Z., et al. Phase III, doubleblindrandomised study comparing lapatinib pluspaclitaxel with placebo plus paclitaxel as firstlinetreatment for metastatic breast cancer. J ClinOncol. 2008:26;5544-52.
46. Cameron D, Casey M, Press M., et al. A phaseIII randomized comparison of lapatinib pluscapecitabine versus capecitabine alone in womenwith advanced breast cancer that has progressedon trastuzumab: Updated efficacy and biomarkeranalyses. Breast Cancer Res Treat. 2008;112:533-543.
47. von Minckwitz G, du Bois A, Schmidt M., et al.Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breastcancer: A german breast group 26/breast internationalgroup 03-05 study. J Clin Oncol. 2009;27:1999-2006